Drug intelligence / Profile preview

bevacizumab + lapatinib

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Bevacizumab + lapatinib is a combination therapy that targets both angiogenesis and HER2/EGFR pathways. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking tumor angiogenesis. Lapatinib is a small molecule tyrosine kinase inhibitor that targets both human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR). This dual-targeting approach aims to overcome resistance mechanisms in cancer treatment by simultaneously inhibiting multiple pathways involved in tumor growth and survival.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFA (Vascular endothelial growth factor A)ERBB4 (Erb-b2 receptor tyrosine kinase 4)

Beyond the preview

Go deeper on bevacizumab + lapatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + lapatinib.

Explore the full profile